Pediatrix Medical Group, Inc. $MD Shares Purchased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. increased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 5.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 801,462 shares of the company’s stock after buying an additional 42,162 shares during the period. Dana Investment Advisors Inc. owned about 0.93% of Pediatrix Medical Group worth $13,424,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. grew its stake in shares of Pediatrix Medical Group by 20.1% in the third quarter. Hillsdale Investment Management Inc. now owns 452,200 shares of the company’s stock worth $7,574,000 after acquiring an additional 75,700 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Pediatrix Medical Group by 25.8% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 14,989 shares of the company’s stock worth $251,000 after purchasing an additional 3,076 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Pediatrix Medical Group by 20.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 827,075 shares of the company’s stock worth $13,854,000 after purchasing an additional 140,577 shares during the period. PNC Financial Services Group Inc. raised its position in Pediatrix Medical Group by 4.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 14,525 shares of the company’s stock valued at $243,000 after purchasing an additional 631 shares in the last quarter. Finally, Public Sector Pension Investment Board boosted its stake in shares of Pediatrix Medical Group by 42.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 409,678 shares of the company’s stock valued at $6,862,000 after buying an additional 122,618 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Insiders Place Their Bets

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the sale, the chief executive officer owned 302,805 shares in the company, valued at approximately $6,785,860.05. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.90% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of MD opened at $19.72 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.66. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99. The stock has a market cap of $1.64 billion, a PE ratio of 10.16 and a beta of 0.76. The firm has a fifty day moving average price of $21.50 and a 200 day moving average price of $19.68.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by ($0.03). Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The firm had revenue of $493.77 million for the quarter, compared to analysts’ expectations of $486.23 million. During the same period in the previous year, the business posted $0.51 EPS. The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on MD. UBS Group upped their target price on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a report on Friday. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. Truist Financial dropped their target price on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.00.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.